scholarly journals Probing heart rate variability to determine parasympathetic dysfunction

2018 ◽  
Vol 6 (10) ◽  
pp. e13713 ◽  
Author(s):  
Jan D. Huizinga ◽  
Karen J. Mathewson ◽  
Yuhong Yuan ◽  
Ji-Hong Chen
Keyword(s):  
Heart Rate ◽  
Heart Rate Variability ◽  
Parasympathetic Dysfunction

scholarly journals Increased inducibility of ventricular tachycardia and decreased heart rate variability in a mouse model for type 1 diabetes: effect of pravastatin

2013 ◽  
Vol 305 (12) ◽  
pp. H1807-H1816 ◽  
Author(s):  
Mohammad Rajab ◽  
Hongwei Jin ◽  
Charles M. Welzig ◽  
Alfred Albano ◽  
Mark Aronovitz ◽  
...  
Keyword(s):  
Heart Rate ◽  
Heart Rate Variability ◽  
Type 1 Diabetes ◽  
Ventricular Tachycardia ◽  
Mouse Model ◽  
Placebo Treatment ◽  
Wild Type ◽  
Parasympathetic Dysfunction ◽  
Akita Mice

Although a reduction in the high-frequency (HF) component of heart rate variability (HRV) is a major complication of diabetes and a risk factor for sudden death, its relationship to ventricular tachycardia (VT) is unknown. We developed a mouse model for the study of VT and its relationship to changes in HRV in the Akita type 1 diabetic mouse. Programmed ventricular stimulation of anesthetized mice demonstrated that Akita mice were more inducible for VT compared with wild-type mice: 78.6% versus 28.6% ( P = 0.007). Optical mapping of perfused hearts demonstrated multifocal breakthroughs that occasionally gave rise to short-lived rotors consistent with focal initiation and maintenance of VT. Treatment of Akita mice with pravastatin, which had been previously shown clinically to decrease ventricular ectopy and to increase HRV, decreased the inducibility of VT: 36.8% compared with 75.0% with placebo treatment ( P = 0.022). The HF fraction of HRV was reduced in Akita mice (48.6 ± 5.2% vs. 70.9 ± 4.8% in wild-type mice, P = 0.005) and was increased compared with placebo treatment in pravastatin-treated mice. Pretreatment of Akita mice with the muscarinic agonist carbamylcholine or the β-adrenergic receptor blocker propranolol decreased the inducibility of VT ( P = 0.001). In conclusion, the increased inducibility of focally initiated VT and reduced HF fraction in Akita mice were partially reversed by both pravastatin treatment and pharmacologic reversal of parasympathetic dysfunction. In this new animal model for the study of the pathogenesis of VT in type 1 diabetes, pravastatin may play a role in the prevention of VT by attenuating parasympathetic dysfunction.

Sign in / Sign up

Export Citation Format

Share Document